NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis $13.12 +0.10 (+0.77%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$13.12 0.00 (-0.03%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CareDx Stock (NASDAQ:CDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CareDx alerts:Sign Up Key Stats Today's Range$12.78▼$13.4050-Day Range$11.81▼$20.6352-Week Range$10.96▼$34.84Volume1.43 million shsAverage Volume1.03 million shsMarket Capitalization$730.52 millionP/E Ratio11.41Dividend YieldN/APrice Target$29.33Consensus RatingModerate Buy Company Overview CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. Read More CareDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreCDNA MarketRank™: CareDx scored higher than 84% of companies evaluated by MarketBeat, and ranked 164th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCareDx has only been the subject of 3 research reports in the past 90 days.Read more about CareDx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($0.90) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is 11.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.64.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is 11.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.08.Price to Book Value per Share RatioCareDx has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CareDx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.33% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in CareDx has recently increased by 1.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.66 Percentage of Shares Shorted12.33% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in CareDx has recently increased by 1.91%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment0.12 News SentimentCareDx has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for CareDx this week, compared to 6 articles on an average week.Search Interest6 people have searched for CDNA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows6 people have added CareDx to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,419,915.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of CareDx is held by insiders.Read more about CareDx's insider trading history. Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address CDNA Stock News HeadlinesInsider Selling: CareDx, Inc. (NASDAQ:CDNA) Director Sells 10,000 Shares of StockJuly 11, 2025 | insidertrades.comCareDx, Inc. (NASDAQ:CDNA) Director Hannah Valantine Sells 10,570 SharesJune 24, 2025 | insidertrades.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. | Timothy Sykes (Ad)CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 33% this week, taking five-year losses to 60%July 23 at 11:02 PM | finance.yahoo.comCareDx to Report Second Quarter 2025 Financial ResultsJuly 23 at 7:05 AM | businesswire.comCareDx (NASDAQ:CDNA) Shares Gap Up - What's Next?July 20, 2025 | americanbankingnews.comCareDx rebounds as draft LCD suggests no change in coverageJuly 18, 2025 | msn.comCareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant RejectionJuly 18, 2025 | businesswire.comSee More Headlines CDNA Stock Analysis - Frequently Asked Questions How have CDNA shares performed this year? CareDx's stock was trading at $21.41 at the start of the year. Since then, CDNA stock has decreased by 38.7% and is now trading at $13.12. How were CareDx's earnings last quarter? CareDx, Inc. (NASDAQ:CDNA) released its quarterly earnings data on Wednesday, April, 30th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm's revenue for the quarter was up 17.6% compared to the same quarter last year. Read the conference call transcript. Who are CareDx's major shareholders? CareDx's top institutional investors include Gagnon Securities LLC (2.78%), Gagnon Advisors LLC (0.82%), QRG Capital Management Inc. (0.04%) and MCF Advisors LLC. Insiders that own company stock include Reginald Seeto, Abhishek Jain, Peter Maag, Alexander L Johnson, William A Hagstrom, Hannah Valantine, Christine Cournoyer and Grace Colon. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Home Depot (HD). Company Calendar Last Earnings4/30/2025Today7/24/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:CDNA CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees740Year FoundedN/APrice Target and Rating Average Price Target for CareDx$29.33 High Price Target$40.00 Low Price Target$24.00 Potential Upside/Downside+123.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$1.15 Trailing P/E Ratio11.41 Forward P/E RatioN/A P/E GrowthN/ANet Income$52.55 million Net Margins19.79% Pretax Margin18.05% Return on Equity21.16% Return on Assets14.25% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio3.84 Sales & Book Value Annual Sales$333.79 million Price / Sales2.19 Cash Flow$1.37 per share Price / Cash Flow9.58 Book Value$7.06 per share Price / Book1.86Miscellaneous Outstanding Shares55,680,000Free Float53,231,000Market Cap$730.52 million OptionableOptionable Beta2.19 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CDNA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredI was wrong about TrumpAddiction. Crime. Corruption. One devastating lie may be fueling it all. A new exposé reveals the hidden ca...Porter & Company | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CareDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.